You are here
ADENOSINE THERAPEUTICS, LLC
UEI: N/A
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
A2a Adenosine Agonists for Diabetic Nephropathy
Amount: $147,326.00DESCRIPTION (provided by applicant): Diabetic nephropathy (DN) accounts for approximately 40% of the cases of renal failure requiring dialysis or transplantation. Moreover, diabetic nephropathy is ass ...
STTRPhase I2005Department of Health and Human Services National Institutes of Health -
A2a Adenosine Blockers for Parkinson's Disease
Amount: $139,176.00DESCRIPTION (PROVIDED BY APPLICANT): Selective antagonists of A2A adenosine receptors have proven to be effective for the treatment of Parkinson's disease (PD) both in animal models and in a human tri ...
STTRPhase I2005Department of Health and Human Services National Institutes of Health -
A2a Adenosine Blockers for Parkinson's Disease
Amount: $139,176.00DESCRIPTION (PROVIDED BY APPLICANT): Selective antagonists of A2A adenosine receptors have proven to be effective for the treatment of Parkinson's disease (PD) both in animal models and in a human tri ...
SBIRPhase I2005Department of Health and Human Services National Institutes of Health -
A2a Adenosine Agonists for Diabetic Nephropathy
Amount: $147,326.00DESCRIPTION (provided by applicant): Diabetic nephropathy (DN) accounts for approximately 40% of the cases of renal failure requiring dialysis or transplantation. Moreover, diabetic nephropathy is ass ...
SBIRPhase I2005Department of Health and Human Services National Institutes of Health -
Novel A2A Adenosine Agonists in Vascular Protection
Amount: $1,247,577.00DESCRIPTION (provided by applicant): This is a phase II SBIR proposal to develop a new drug eluting stent to prevent restenosis. It is a 3-way collaboration between Adenosine Therapeutics, LLC, Setago ...
STTRPhase II2004Department of Health and Human Services National Institutes of Health -
Antagonists of A2B Receptors Improve Insulin Sensitivity
Amount: $1,424,440.00DESCRIPTION (provided by applicant): This is a phase II SBIR grant to develop a new therapy for the treatment of type II diabetes. Adenosine Therapeutics, LLC (ATL) is a biotechnology company started ...
SBIRPhase II2004Department of Health and Human Services National Institutes of Health -
A2A Adenosine Receptor Agonist for the Treatment of IBD
Amount: $673,023.00DESCRIPTION (provided by applicant): Adenosine Therapeutics, LLC (ATL) is a biotechnology company started in Charlottesville, Virginia in 1999. ATL owns patents on the formulation and use of a family ...
SBIRPhase I2004Department of Health and Human Services National Institutes of Health -
Novel A2A Adenosine Agonists in Vascular Protection
Amount: $1,247,580.00DESCRIPTION (provided by applicant): This is a phase II SBIR proposal to develop a new drug eluting stent to prevent restenosis. It is a 3-way collaboration between Adenosine Therapeutics, LLC, Setago ...
SBIRPhase II2004Department of Health and Human Services National Institutes of Health -
A2a Adenosine Receptors and Equine Sepsis
Amount: $75,000.00NON-TECHNICAL SUMMARY: This is a phase I SBIR proposal by Adenosine Therapeutics for 6 months of support to synthesize and evaluate novel compounds as agonists of equine A2A adenosine receptors. Some ...
SBIRPhase I2003Department of Agriculture -
Long Acting Agonists of Adenosine A2a Receptors
Amount: $100,885.00DESCRIPTION (provided by applicant): Adenosine is an endogenous nucleoside that exerts its physiological effects through four G-protein coupled receptors A1, A2A, A2B, and A3. Adenosine Therapeutics ...
SBIRPhase I2003Department of Health and Human Services National Institutes of Health
